

SUPPLEMENTAL INFORMATION

This document contains information on the distribution of 720 confirmed cancer cases identified in the United Kingdom's Clinical Practice Research Datalink (CPRD) by data source (primary, hospital, and cancer registry data) for the 10 study cancer cases combined and by cancer type. We present the same information in tabular and graphical formats. Additional information can be found in these publications:

- Parent study: Kaye JA, Margulis AV, Fortuny J, McQuay LJ, Plana E, Bartsch JL, Bui CL, Perez-Gutthann S, Arana A. Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias. *Pharmacotherapy*. 2017 Jun;37(6):673-683. doi: 10.1002/phar.1932.
- Validation study: Margulis AV, Fortuny J, Kaye JA, Calingaert B, Reynolds M, Plana E, McQuay LJ, Atsma WJ, Franks B, de Vogel S, Perez-Gutthann S, Arana A. Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom. *Epidemiology*. 2018 Mar;29(2):308-313. doi: 10.1097/EDE.0000000000000786.
- Assessment of value of free-text comments for cancer case validation: Margulis AV, Fortuny J, Kaye JA, Calingaert B, Reynolds M, Plana E, McQuay LJ, Atsma WJ, Franks B, de Vogel S, Perez-Gutthann S, Arana A. Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom. *Epidemiology*. 2018 Sep;29(5):e41-e42. doi: 10.1097/EDE.0000000000000856.

LIST OF TABLES

Table 1.	Cancer Cases by Data Source Within CPRD: Primary Care (GOLD), Hospital (HES) and Cancer Registry (NCDR) Data	3
Table 2.	Characteristics of Study Patients by Source of Cancer Data and Drug at Cohort Entry	4

LIST OF FIGURES

Figure 1.	Cancer Cases by Data Source Within CPRD: All Cancers Combined	114
Figure 2.	Cancer Cases by Data Source Within CPRD: Bladder Cancer	125
Figure 3.	Cancer Cases by Data Source Within CPRD: Breast Cancer	136
Figure 4.	Cancer Cases by Data Source Within CPRD: Colorectal Cancer	147
Figure 5.	Cancer Cases by Data Source Within CPRD: Uterine Cancer	158
Figure 6.	Cancer Cases by Data Source Within CPRD: Kidney Cancer	169
Figure 7.	Cancer Cases by Data Source Within CPRD: Lung and Bronchus Cancer	1740
Figure 8.	Cancer Cases by Data Source Within CPRD: Non-Hodgkin Lymphoma	1844
Figure 9.	Cancer Cases by Data Source Within CPRD: Pancreatic Cancer	1942
Figure 10.	Cancer Cases by Data Source Within CPRD: Prostate Cancer	2043
Figure 11.	Cancer Cases by Data Source Within CPRD: Skin Melanoma	2144

Table 1. Cancer Cases by Data Source Within CPRD: Primary Care (GOLD), Hospital (HES) and Cancer Registry (NCDR) Data

Cancer type	Total	Data Source, n (%)									
		GOLD ^a	HES ^a	NCDR ^a	GOLD only ^b	HES only ^b	NCDR only ^b	GOLD and HES only	GOLD and NCDR only	HES and NCDR only	GOLD, HES, and NCDR ^c
All types	720	492 (68)	581 (81)	608 (84)	22 (3)	56 (8)	54 (8)	34 (5)	63 (9)	118 (16)	373 (52)
Bladder	113	70 (62)	104 (92)	76 (67)	5 (4)	18 (16)	3 (3)	14 (12)	1 (1)	22 (19)	50 (44)
Breast	144	130 (90)	120 (83)	131 (91)	4 (3)	3 (2)	4 (3)	6 (4)	16 (11)	7 (5)	104 (72)
Colorectal	87	56 (64)	76 (87)	77 (89)	1 (1)	8 (9)	7 (8)	1 (1)	3 (3)	16 (18)	51 (59)
Corpus uteri	28	16 (57)	22 (79)	27 (96)	0 (0)	1 (4)	3 (11)	0 (0)	3 (11)	8 (29)	13 (46)
Kidney and renal pelvis	28	10 (36)	24 (86)	24 (86)	0 (0)	4 (14)	2 (7)	0 (0)	2 (7)	12 (43)	8 (29)
Lung and bronchus	91	43 (47)	68 (75)	85 (93)	0 (0)	4 (4)	17 (19)	2 (2)	6 (7)	27 (30)	35 (38)
Non-Hodgkin lymphoma	29	19 (66)	24 (83)	23 (79)	0 (0)	4 (14)	2 (7)	2 (7)	3 (10)	4 (14)	14 (48)
Pancreas	21	10 (48)	15 (71)	16 (76)	1 (5)	3 (14)	4 (19)	1 (5)	1 (5)	4 (19)	7 (33)
Prostate	151	120 (79)	109 (72)	127 (84)	7 (5)	9 (6)	10 (7)	8 (5)	25 (17)	12 (8)	80 (53)
Skin melanoma	28	18 (64)	19 (68)	22 (79)	4 (14)	2 (7)	2 (7)	0 (0)	3 (11)	6 (21)	11 (39)

CPRD = Clinical Practice Research Datalink; GOLD = General Practitioner Online Database; HES = Hospital Episode Statistics; NCDR = National Cancer Data Repository.

^a Cases identifiable in this data source (ie, including cases identifiable in any of the other two data sources).

^b Cases identifiable only in this data source (ie, excluding cases identifiable in either of the other two data sources).

^c Cases identifiable in all the three sources (ie, overlap among the three sources).

Formatted: Space Before: 0.4 line, After: 0.4 line

Formatted: Space Before: 0.4 line, After: 0.4 line

Formatted: Space Before: 0.4 line, After: 0.4 line

Formatted: Space Before: 0.4 line, After: 0.4 line

Formatted: Space Before: 0.4 line, After: 0.4 line

Formatted: Space Before: 0.4 line, After: 0.4 line

Formatted: Space Before: 0.4 line, After: 0.4 line

Formatted: Space Before: 0.4 line, After: 0.4 line

Formatted: Space Before: 0.4 line, After: 0.4 line

Formatted: Space Before: 0.4 line, After: 0.4 line

Formatted: Space Before: 0.4 line, After: 0.4 line

Formatted: Space Before: 0.4 line, After: 0.4 line

Formatted: Space Before: 0.4 line, After: 0.4 line

Formatted: Space Before: 0.4 line, After: 0.4 line

Table 2. Characteristics of Study Patients by Source of Cancer Data and Drug at Cohort Entry

	All types				Bladder				Breast				Colorectal			
	In GOLD data		Not in GOLD data		In GOLD data		Not in GOLD data		In GOLD data		Not in GOLD data		In GOLD data		Not in GOLD data	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Total	492	(68.3)	228	(31.7)	70	(61.9)	43	(38.1)	130	(90.3)	14	(9.7)	56	(64.4)	31	(35.6)
Age at outcome																
18-54	40	(88.9)	5	(11.1)	1	(100)	0	(0.0)	25	(96.2)	1	(3.8)	0	(0.0)	0	(0.0)
55-64	83	(72.2)	32	(27.8)	9	(56.3)	7	(43.8)	27	(96.4)	1	(3.6)	5	(71.4)	2	(28.6)
65-74	134	(67.7)	64	(32.3)	18	(66.7)	9	(33.3)	29	(85.3)	5	(14.7)	18	(69.2)	8	(30.8)
75+	235	(64.9)	127	(35.1)	42	(60.9)	27	(39.1)	49	(87.5)	7	(12.5)	33	(61.1)	21	(38.9)
Sex																
Male	230	(68.7)	105	(31.3)	45	(68.2)	21	(31.8)	0	(0.0)	0	(0.0)	21	(63.6)	12	(36.4)
Female	262	(68.1)	123	(31.9)	25	(53.2)	22	(46.8)	130	(90.3)	14	(9.7)	35	(64.8)	19	(35.2)
Year of outcome																
2004 and 2005	49	(72.1)	19	(27.9)	9	(75.0)	3	(25.0)	12	(100)	0	(0.0)	4	(66.7)	2	(33.3)
2006 to 2008	230	(72.6)	87	(27.4)	33	(67.3)	16	(32.7)	59	(93.7)	4	(6.3)	24	(70.6)	10	(29.4)
2009 and 2010	213	(63.6)	122	(36.4)	28	(53.8)	24	(46.2)	59	(85.5)	10	(14.5)	28	(59.6)	19	(40.4)
Increased cardiovascular risk ^a	295	(65.4)	156	(34.6)	48	(63.2)	28	(36.8)	57	(87.7)	8	(12.3)	36	(63.2)	21	(36.8)

	All types				Bladder				Breast				Colorectal			
	In GOLD		Not in		In GOLD		Not in		In GOLD		Not in		In GOLD		Not in	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Index of Multiple Deprivation (quintiles)																
Q1	121	(70.8)	50	(29.2)	19	(61.3)	12	(38.7)	27	(93.1)	2	(6.9)	13	(61.9)	8	(38.1)
Q2	140	(68.0)	66	(32.0)	19	(57.6)	14	(42.4)	41	(89.1)	5	(10.9)	14	(58.3)	10	(41.7)
Q3	96	(70.6)	40	(29.4)	16	(80.0)	4	(20.0)	28	(93.3)	2	(6.7)	11	(68.8)	5	(31.3)
Q4	67	(64.4)	37	(35.6)	8	(72.7)	3	(27.3)	19	(82.6)	4	(17.4)	10	(62.5)	6	(37.5)
Q5	68	(66.0)	35	(34.0)	8	(44.4)	10	(55.6)	15	(93.8)	1	(6.3)	8	(80.0)	2	(20.0)
Smoking																
Current	59	(61.5)	37	(38.5)	7	(46.7)	8	(53.3)	11	(91.7)	1	(8.3)	4	(66.7)	2	(33.3)
Former	248	(67.6)	119	(32.4)	44	(66.7)	22	(33.3)	49	(87.5)	7	(12.5)	28	(62.2)	17	(37.8)
Non-smoker	185	(72.3)	71	(27.7)	19	(59.4)	13	(40.6)	70	(92.1)	6	(7.9)	24	(66.7)	12	(33.3)
Unknown	0	(0.0)	1	(100)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Body mass index																
< 20	15	(65.2)	8	(34.8)	4	(57.1)	3	(42.9)	5	(100)	0	(0.0)	0	(0.0)	1	(100)
20 to < 25	113	(73.4)	41	(26.6)	13	(65.0)	7	(35.0)	23	(95.8)	1	(4.2)	19	(73.1)	7	(26.9)
25 to < 30	139	(70.2)	59	(29.8)	26	(81.3)	6	(18.8)	33	(89.2)	4	(10.8)	14	(60.9)	9	(39.1)
30 to < 40	81	(65.3)	43	(34.7)	9	(45.0)	11	(55.0)	28	(93.3)	2	(6.7)	7	(63.6)	4	(36.4)
40+	9	(60.0)	6	(40.0)	0	(0.0)	0	(0.0)	3	(60.0)	2	(40.0)	0	(0.0)	0	(0.0)
Unknown	135	(65.5)	71	(34.5)	18	(52.9)	16	(47.1)	38	(88.4)	5	(11.6)	16	(61.5)	10	(38.5)
Hypertension (diagnostic codes and/or medications)	467	(67.7)	223	(32.3)	68	(61.8)	42	(38.2)	121	(90.3)	13	(9.7)	55	(64.0)	31	(36.0)

	All types				Bladder				Breast				Colorectal			
	In GOLD data		Not in GOLD data		In GOLD data		Not in GOLD data		In GOLD data		Not in GOLD data		In GOLD data		Not in GOLD data	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Diabetes (diagnostic codes and/or medications)	74	(62.2)	45	(37.8)	5	(31.3)	11	(68.8)	14	(93.3)	1	(6.7)	7	(46.7)	8	(53.3)

GOLD = General Practitioner Online Database.

^a Increased cardiovascular risk was defined as having evidence or history of diabetes, acute myocardial infarction, heart failure, coronary heart disease, atrial fibrillation, stroke, transient ischemic attack, peripheral artery disease, or peripheral vascular disease; or meeting more than one of these criteria: being a current smoker, having a diagnosis of dyslipidemia, having a diagnosis of hypertension.

Table 2. Characteristics of Study Patients by Source of Cancer Data and Drug at Cohort Entry (continuation)

	Corpus uteri				Kidney and renal pelvis				Lung and bronchus				Non-Hodgkin lymphoma			
	In GOLD		Not in		In GOLD		Not in		In GOLD		Not in		In GOLD		Not in	
	data		GOLD data		data		GOLD data		data		GOLD data		data		GOLD data	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Total	16	(57.1)	12	(42.9)	10	(35.7)	18	(64.3)	43	(47.3)	48	(52.7)	19	(65.5)	10	(34.5)
Age at outcome																
18-54	2	(66.7)	1	(33.3)	0	(0.0)	1	(100)	4	(80.0)	1	(20.0)	1	(100)	0	(0.0)
55-64	4	(80.0)	1	(20.0)	4	(57.1)	3	(42.9)	6	(37.5)	10	(62.5)	6	(100)	0	(0.0)
65-74	5	(41.7)	7	(58.3)	3	(50.0)	3	(50.0)	12	(50.0)	12	(50.0)	5	(41.7)	7	(58.3)
75+	5	(62.5)	3	(37.5)	3	(21.4)	11	(78.6)	21	(45.7)	25	(54.3)	7	(70.0)	3	(30.0)
Sex																
Male	0	(0.0)	0	(0.0)	7	(43.8)	9	(56.3)	24	(55.8)	19	(44.2)	10	(58.8)	7	(41.2)
Female	16	(57.1)	12	(42.9)	3	(25.0)	9	(75.0)	19	(39.6)	29	(60.4)	9	(75.0)	3	(25.0)
Year of outcome																
2004 and 2005	1	(33.3)	2	(66.7)	2	(40.0)	3	(60.0)	2	(28.6)	5	(71.4)	2	(66.7)	1	(33.3)
2006 to 2008	7	(63.6)	4	(36.4)	6	(54.5)	5	(45.5)	24	(49.0)	25	(51.0)	12	(80.0)	3	(20.0)
2009 and 2010	8	(57.1)	6	(42.9)	2	(16.7)	10	(83.3)	17	(48.6)	18	(51.4)	5	(45.5)	6	(54.5)
Increased cardiovascular risk ^a	8	(50.0)	8	(50.0)	7	(33.3)	14	(66.7)	40	(54.1)	34	(45.9)	9	(56.3)	7	(43.8)
Index of Multiple Deprivation (quintiles)																
Q1	4	(100)	0	(0.0)	2	(25.0)	6	(75.0)	12	(63.2)	7	(36.8)	4	(66.7)	2	(33.3)
Q2	3	(42.9)	4	(57.1)	4	(57.1)	3	(42.9)	11	(50.0)	11	(50.0)	4	(50.0)	4	(50.0)
Q3	5	(71.4)	2	(28.6)	3	(50.0)	3	(50.0)	5	(27.8)	13	(72.2)	0	(0.0)	2	(100)
Q4	2	(33.3)	4	(66.7)	0	(0.0)	3	(100)	8	(61.5)	5	(38.5)	5	(71.4)	2	(28.6)
Q5	2	(50.0)	2	(50.0)	1	(25.0)	3	(75.0)	7	(36.8)	12	(63.2)	6	(100)	0	(0.0)

	Corpus uteri				Kidney and renal pelvis				Lung and bronchus				Non-Hodgkin lymphoma			
	In GOLD data		Not in GOLD data		In GOLD data		Not in GOLD data		In GOLD data		Not in GOLD data		In GOLD data		Not in GOLD data	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Smoking																
Current	1	(100)	0	(0.0)	1	(16.7)	5	(83.3)	16	(51.6)	15	(48.4)	3	(100)	0	(0.0)
Former	4	(40.0)	6	(60.0)	7	(50.0)	7	(50.0)	23	(45.1)	28	(54.9)	12	(63.2)	7	(36.8)
Non-smoker	11	(64.7)	6	(35.3)	2	(25.0)	6	(75.0)	4	(44.4)	5	(55.6)	4	(57.1)	3	(42.9)
Unknown	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Body mass index																
< 20	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(33.3)	4	(66.7)	0	(0.0)	0	(0.0)
20 to < 25	1	(33.3)	2	(66.7)	0	(0.0)	4	(100)	10	(52.6)	9	(47.4)	4	(80.0)	1	(20.0)
25 to < 30	4	(57.1)	3	(42.9)	3	(33.3)	6	(66.7)	13	(54.2)	11	(45.8)	7	(70.0)	3	(30.0)
30 to < 40	3	(42.9)	4	(57.1)	3	(60.0)	2	(40.0)	4	(28.6)	10	(71.4)	4	(80.0)	1	(20.0)
40+	2	(66.7)	1	(33.3)	0	(0.0)	1	(100)	0	(0.0)	1	(100)	1	(50.0)	1	(50.0)
Unknown	6	(75.0)	2	(25.0)	4	(44.4)	5	(55.6)	14	(51.9)	13	(48.1)	3	(42.9)	4	(57.1)
Hypertension (diagnostic codes and/or medications)	15	(55.6)	12	(44.4)	10	(37.0)	17	(63.0)	41	(46.6)	47	(53.4)	18	(64.3)	10	(35.7)
Diabetes (diagnostic codes and/or medications)	3	(60.0)	2	(40.0)	2	(28.6)	5	(71.4)	13	(59.1)	9	(40.9)	4	(80.0)	1	(20.0)

^a Increased cardiovascular risk was defined as having evidence or history of diabetes, acute myocardial infarction, heart failure, coronary heart disease, atrial fibrillation, stroke, transient ischemic attack, peripheral artery disease, or peripheral vascular disease; or meeting more than one of these criteria: being a current smoker, having a diagnosis of dyslipidemia, having a diagnosis of hypertension.

Table 2. Characteristics of Study Patients by Source of Cancer Data and Drug at Cohort Entry (continuation)


	Pancreas				Prostate				Skin melanoma			
	In GOLD data		Not in GOLD data		In GOLD data		Not in GOLD data		In GOLD data		Not in GOLD data	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Total	10	(47.6)	11	(52.4)	120	(79.5)	31	(20.5)	18	(64.3)	10	(35.7)
Age at outcome												
18-54	1	(100)	0	(0.0)	4	(100)	0	(0.0)	2	(66.7)	1	(33.3)
55-64	2	(66.7)	1	(33.3)	17	(81.0)	4	(19.0)	3	(50.0)	3	(50.0)
65-74	3	(75.0)	1	(25.0)	36	(80.0)	9	(20.0)	5	(62.5)	3	(37.5)
75+	4	(30.8)	9	(69.2)	63	(77.8)	18	(22.2)	8	(72.7)	3	(27.3)
Sex												
Male	0	(0.0)	5	(100)	120	(79.5)	31	(20.5)	3	(75.0)	1	(25.0)
Female	10	(62.5)	6	(37.5)	0	(0.0)	0	(0.0)	15	(62.5)	9	(37.5)
Year of outcome												
2004 and 2005	0	(0.0)	2	(100)	15	(93.8)	1	(6.3)	2	(100)	0	(0.0)
2006 to 2008	5	(45.5)	6	(54.5)	52	(82.5)	11	(17.5)	8	(72.7)	3	(27.3)
2009 and 2010	5	(62.5)	3	(37.5)	53	(73.6)	19	(26.4)	8	(53.3)	7	(46.7)
Increased cardiovascular risk ^a	7	(46.7)	8	(53.3)	74	(77.1)	22	(22.9)	9	(60.0)	6	(40.0)
Index of Multiple Deprivation (quintiles)												
Q1	2	(40.0)	3	(60.0)	35	(81.4)	8	(18.6)	3	(60.0)	2	(40.0)
Q2	3	(60.0)	2	(40.0)	37	(78.7)	10	(21.3)	4	(57.1)	3	(42.9)
Q3	1	(33.3)	2	(66.7)	23	(79.3)	6	(20.7)	4	(80.0)	1	(20.0)
Q4	2	(33.3)	4	(66.7)	8	(72.7)	3	(27.3)	5	(62.5)	3	(37.5)
Q5	2	(100)	0	(0.0)	17	(81.0)	4	(19.0)	2	(66.7)	1	(33.3)

	Pancreas				Prostate				Skin melanoma			
	In GOLD data		Not in GOLD data		In GOLD data		Not in GOLD data		In GOLD data		Not in GOLD data	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Smoking												
Current	1	(33.3)	2	(66.7)	13	(76.5)	4	(23.5)	2	(100)	0	(0.0)
Former	4	(40.0)	6	(60.0)	67	(81.7)	15	(18.3)	10	(71.4)	4	(28.6)
Non-smoker	5	(62.5)	3	(37.5)	40	(78.4)	11	(21.6)	6	(50.0)	6	(50.0)
Unknown	0	(0.0)	0	(0.0)	0	(0.0)	1	(100)	0	(0.0)	0	(0.0)
Body mass index												
< 20	0	(0.0)	0	(0.0)	3	(100)	0	(0.0)	1	(100)	0	(0.0)
20 to < 25	4	(57.1)	3	(42.9)	33	(82.5)	7	(17.5)	6	(100)	0	(0.0)
25 to < 30	3	(60.0)	2	(40.0)	32	(74.4)	11	(25.6)	4	(50.0)	4	(50.0)
30 to < 40	1	(50.0)	1	(50.0)	16	(72.7)	6	(27.3)	6	(75.0)	2	(25.0)
40+	0	(0.0)	0	(0.0)	3	(100)	0	(0.0)	0	(0.0)	0	(0.0)
Unknown	2	(28.6)	5	(71.4)	33	(82.5)	7	(17.5)	1	(20.0)	4	(80.0)
Hypertension (diagnostic codes and/or medications)	10	(47.6)	11	(52.4)	114	(79.2)	30	(20.8)	15	(60.0)	10	(40.0)
Diabetes (diagnostic codes and/or medications)	5	(62.5)	3	(37.5)	21	(87.5)	3	(12.5)	0	(0.0)	2	(100)

^a Increased cardiovascular risk was defined as having evidence or history of diabetes, acute myocardial infarction, heart failure, coronary heart disease, atrial fibrillation, stroke, transient ischemic attack, peripheral artery disease, or peripheral vascular disease; or meeting more than one of these criteria: being a current smoker, having a diagnosis of dyslipidemia, having a diagnosis of hypertension.


PROPORTIONAL VENN DIAGRAMS

Figure 1. Cancer Cases by Data Source Within CPRD: All Cancers Combined



CPRD = Clinical Practice Research Datalink; GOLD = General Practitioner Online Database; HES = Hospital Episode Statistics.


Figure 2. Cancer Cases by Data Source Within CPRD: Bladder Cancer



CPRD = Clinical Practice Research Datalink; GOLD = General Practitioner Online Database; HES = Hospital Episode Statistics.


Figure 3. Cancer Cases by Data Source Within CPRD: Breast Cancer

n = 144



CPRD = Clinical Practice Research Datalink; GOLD = General Practitioner Online Database; HES = Hospital Episode Statistics.


Figure 4. Cancer Cases by Data Source Within CPRD: Colorectal Cancer



CPRD = Clinical Practice Research Datalink; GOLD = General Practitioner Online Database; HES = Hospital Episode Statistics.


Figure 5. Cancer Cases by Data Source Within CPRD: Uterine Cancer

n = 28




CPRD = Clinical Practice Research Datalink; GOLD = General Practitioner Online Database; HES = Hospital Episode Statistics.

Figure 6. Cancer Cases by Data Source Within CPRD: Kidney Cancer



CPRD = Clinical Practice Research Datalink; GOLD = General Practitioner Online Database; HES = Hospital Episode Statistics.


Figure 7. Cancer Cases by Data Source Within CPRD: Lung and Bronchus Cancer



CPRD = Clinical Practice Research Datalink; GOLD = General Practitioner Online Database; HES = Hospital Episode Statistics.


Figure 8. Cancer Cases by Data Source Within CPRD: Non-Hodgkin Lymphoma

n = 29



CPRD = Clinical Practice Research Datalink; GOLD = General Practitioner Online Database; HES = Hospital Episode Statistics.


Figure 9. Cancer Cases by Data Source Within CPRD: Pancreatic Cancer



CPRD = Clinical Practice Research Datalink; GOLD = General Practitioner Online Database; HES = Hospital Episode Statistics.


Figure 10. Cancer Cases by Data Source Within CPRD: Prostate Cancer

n = 151



CPRD = Clinical Practice Research Datalink; GOLD = General Practitioner Online Database; HES = Hospital Episode Statistics.

Figure 11. Cancer Cases by Data Source Within CPRD: Skin Melanoma



CPRD = Clinical Practice Research Datalink; GOLD = General Practitioner Online Database; HES = Hospital Episode Statistics.